Biocon commercial rights on biosimilar adalimumab extends to global markets Farhat Nasim8 May 2019 4:15 AM GMTBiocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arr...
Lupin to add GLP 1 analog to its diabetes portfolio in India Ruby Khatun Khatun13 Sep 2017 9:37 AM GMTMumbai: Lupin plans to introduce a new class of diabetes drugs in India through in-licensing agreements in order to enhance its diabetes drugs...
